TAIHUA: Chinese biopharmaceutical - new to AIM

A good report and one of 5 recommended companies from Hoodless Brennan

• Substantial room for profit growth as
range expands to include injectables
and export licences are obtained for
South Korea and EU
• Growth in hospital client list for own
brand range of herbal medicines
• PE of 6.2x based on 2006 numbersgood
comparison with UK biotech peers
• Low cost base- admin expense just 8%admin expense just 8%
of 2005 sales